Table 4.

Results of the CUA of incobotulinumtoxinA compared against SoC alone in the treatment of sialorrhea

Model outputs	IncobotulinumtoxinA	SoC alone	Incremental difference
Total costs (A$)
IncobotulinumtoxinA therapy	A$6634	–	A$6634
Other care	A$732	A$1128	− A$396
Total	A$7365	A$1128	A$6238
QALYs	3.02	2.75	0.27
ICER			A$23,445

NB. All outputs are discounted at 5% per annum

CUA cost-utility analysis, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, SoC standard of care